```html

Secondary Hyperparathyroidism – A Complete Patient Guide

Overview

Secondary hyperparathyroidism (SHPT) is a condition in which the parathyroid glands produce excess parathyroid hormone (PTH) as a physiologic response to another chronic problem that lowers calcium levels or impairs vitamin D metabolism. Unlike primary hyperparathyroidism—where an intrinsic gland problem drives PTH elevation—SHPT is “secondary” to disorders such as chronic kidney disease (CKD), vitamin D deficiency, or severe malabsorption.

• Who it affects: Adults with advanced CKD (stages 3‑5) are the most common group; however, patients with prolonged vitamin D deficiency, intestinal malabsorption, or certain hereditary bone diseases can also develop SHPT.
• Prevalence: Approximately 30‑40 % of patients with CKD stage 5 on dialysis have clinically significant SHPT (National Kidney Foundation, 2023). In the general population, SHPT is far less common, with estimates ranging from 1‑2 % among older adults with chronic vitamin D insufficiency.

Symptoms

Because SHPT is driven by an underlying disorder, symptoms often overlap with that primary disease. When PTH becomes markedly elevated, classic features of hyperparathyroidism can appear:

Bone‑related symptoms

• Bone pain: Dull, aching pain in the spine, ribs, hips, or long bones.
• Fractures: Increased risk of fractures, especially vertebral or wrist fractures, due to weakened bone (renal osteodystrophy).
• Osteitis fibrosa cystica: Rare, but severe bone remodeling leading to “brown tumors.”

Kidney‑related symptoms (common in CKD‑related SHPT)

• Calcification of blood vessels and soft tissues, leading to hypertension.
• Worsening renal function or formation of kidney stones (though stones are more typical of primary disease).

Neuromuscular symptoms

• Muscle weakness or fatigue.
• Generalized bone tenderness.
• Paresthesia (tingling) in the hands or feet, especially when calcium is low.

Gastrointestinal & constitutional signs

• Loss of appetite, nausea, or vomiting.
• Unexplained weight loss.
• Depression or difficulty concentrating (linked to calcium fluctuations).

Many patients with early‑stage SHPT are asymptomatic; the condition is usually discovered during routine labs showing high PTH, low or normal calcium, and abnormal phosphate.

Causes and Risk Factors

SHPT results when the body attempts to compensate for low serum calcium, high phosphate, or deficient active vitamin D (1,25‑(OH)₂D). The most common etiologies include:

Chronic Kidney Disease (CKD)

• Reduced renal conversion of vitamin D to its active form.
• Phosphate retention leading to high serum phosphate, which directly stimulates PTH secretion.
• Decreased calcium reabsorption in the distal tubule.

Vitamin D Deficiency

• Limited sun exposure, malabsorption (celiac disease, bariatric surgery), or inadequate dietary intake.
• Chronic liver disease impairing 25‑hydroxylation of vitamin D.

Malabsorption Syndromes

• Inflammatory bowel disease, short bowel syndrome, or pancreatic insufficiency.

Medications & Other Conditions

• Phosphate binders that are poorly absorbed, leading to persistent hyperphosphatemia.
• Anticonvulsants (e.g., phenytoin) that increase vitamin D catabolism.
• Rare genetic disorders such as Familial Hypocalciuric Hypercalcemia (though this is usually primary).

Risk Factor Summary

Risk Factor	Why It Increases Risk
CKD stage 3‑5 or dialysis	Impaired phosphate excretion & vitamin D activation
Serum 25‑OH vitamin D < 20 ng/mL	Reduced calcium absorption
High dietary phosphate intake	Stimulates PTH via hypocalcemia
Age > 65 years	Declining kidney function & vitamin D synthesis
Obesity	Sequestration of vitamin D in adipose tissue

Diagnosis

Diagnosing SHPT involves a combination of laboratory evaluation, imaging, and clinical correlation with the underlying disease.

Laboratory Tests

• Intact Parathyroid Hormone (iPTH): Elevated (often > 300 pg/mL in severe CKD‑related SHPT).
• Serum Calcium: Usually low‑normal or mildly low; may be normal if calcium supplements are taken.
• Serum Phosphate: Frequently high in CKD patients.
• 25‑OH Vitamin D: Measured to assess deficiency; <20 ng/mL indicates deficiency.
• 1,25‑(OH)₂ Vitamin D: Low in CKD due to reduced renal 1α‑hydroxylase activity.
• Creatinine & eGFR: To stage kidney disease.
• Alkaline phosphatase (bone isoform): Elevated when high bone turnover is present.

Imaging Studies

• Dual‑energy X‑ray absorptiometry (DXA): Detects reduced bone mineral density.
• Bone scintigraphy or X‑rays: May reveal subperiosteal erosions or brown tumors in severe cases.
• Cardiac & vascular ultrasound: Assess for ectopic calcifications, especially in dialysis patients.

Diagnostic Criteria (KDIGO 2023)

For patients with CKD stage 5 on dialysis, SHPT is considered when iPTH > 2 × upper normal limit of the assay, accompanied by either hyperphosphatemia or low vitamin D.

Treatment Options

Treatment aims to correct the underlying disturbance, control PTH levels, protect bone health, and prevent vascular calcifications.

Pharmacologic Therapy

• Active vitamin D analogs (calcitriol, alfacalcidol): Bypass the kidney’s 1α‑hydroxylase step and suppress PTH synthesis. Start with low doses to avoid hypercalcemia.
• Vitamin D receptor activators (e.g., paricalcitol, doxercalciferol): Provide PTH suppression with a lower risk of calcium/phosphate elevation.
• Phosphate binders:
  • Calcium‑based binders (calcium acetate, calcium carbonate) reduce serum phosphate but increase calcium load.
  • Non‑calcium binders (sevelamer, lanthanum) are preferred in patients at risk for hypercalcemia.
• Calcimimetics (cinacalcet, etelcalcetide): Increase the sensitivity of the calcium‑sensing receptor on parathyroid cells, lowering PTH secretion. Particularly useful for dialysis patients with refractory SHPT.
• Bisphosphonates: Occasionally used when severe bone turnover coexists, but they do not address the underlying PTH excess.

Surgical Intervention

Parathyroidectomy is reserved for patients with:

• PTH persistently > 800 pg/mL despite optimal medical therapy.
• Severe symptomatic bone disease or calciphylaxis.
• Refractory hypercalcemia.

The procedure can be subtotal (3½ glands removed) or total with autotransplantation of a small gland fragment to the forearm.

Lifestyle & Dietary Measures

• Phosphate restriction: Limit processed foods, sodas, and dairy products high in phosphate additives.
• Optimized calcium intake: 1,000–1,200 mg/day for most adults, sourced from food rather than supplements unless directed.
• Vitamin D supplementation: 800–1,000 IU/day of cholecalciferol (D3) for deficiency; higher doses may be required under physician supervision.
• Regular physical activity: Weight‑bearing and resistance exercises improve bone density.
• Smoking cessation & moderate alcohol use: Both improve bone health and cardiovascular outcomes.

Living with Secondary Hyperparathyroidism

Successful long‑term management blends medical treatment with daily habits that support bone and kidney health.

Medication Adherence

• Use a weekly pill organizer; set phone reminders.
• Know the timing of phosphate binders (taken with meals).
• Report any new symptoms of hypercalcemia (nausea, constipation, confusion) promptly.

Nutrition Tips

• Read food labels for “phosphate” or “added phosphorus” (common in deli meats, cheese spreads, and cola).
• Include vitamin D‑rich foods: fatty fish, fortified milk, and egg yolks.
• Maintain adequate hydration (unless fluid‑restricted for CKD).

Monitoring

• Laboratory tests every 1–3 months in dialysis patients; every 6–12 months in earlier CKD stages.
• Annual DXA scan to track bone mineral density.
• Regular dental check‑ups—vascular calcifications can affect oral health.

Emotional & Social Support

• Join CKD or bone‑health support groups (online forums, local kidney foundations).
• Consider counseling if chronic illness leads to anxiety or depression.

Prevention

Because SHPT is usually a consequence of another disease, primary prevention focuses on early identification and treatment of the root cause.

• Screen for vitamin D deficiency: At least once yearly for adults over 50, or sooner if risk factors exist.
• Early CKD detection: Annual eGFR and urine albumin checks in people with diabetes, hypertension, or a family history of kidney disease.
• Maintain a balanced diet low in excess phosphate and adequate in calcium & vitamin D.
• Control blood pressure and blood glucose: Reduces progression of CKD.
• Avoid nephrotoxic medications when possible (e.g., NSAIDs, certain antibiotics).

Complications

If untreated or poorly controlled, SHPT can lead to serious health problems:

• Renal osteodystrophy: Mixed high‑turnover (osteitis fibrosa) and low‑turnover bone disease, causing fractures and deformities.
• Vascular and soft‑tissue calcifications: Leads to arterial stiffness, hypertension, left‑ventricular hypertrophy, and increased cardiovascular mortality.
• Calciphylaxis: Rare, painful skin necrosis with high mortality; associated with very high PTH and calcium‑phosphate product.
• Persistent hyperphosphatemia: Worsens CKD progression.
• Secondary infections: Due to frequent hospital visits for dialysis and procedures.

When to Seek Emergency Care

References

• Mayo Clinic. “Secondary hyperparathyroidism.” mayoclinic.org.
• National Kidney Foundation. KDIGO Clinical Practice Guideline for the Management of CKD-MBD. 2023.
• Cleveland Clinic. “Hyperparathyroidism.” clevelandclinic.org.
• U.S. National Institutes of Health. “Vitamin D Fact Sheet for Health Professionals.” 2022.
• World Health Organization. “Guidelines on Nutrition for Kidney Health.” 2021.
• J. H. Ketteler et al., “The management of secondary hyperparathyroidism in chronic kidney disease: A comprehensive review.” *Kidney International*, 2022.

```